Amyloid precursor protein-induced axonopathies are independent of amyloid-β peptides
Open accessAbstract
Overexpression of amyloid precursor protein (APP), as well as mutations in the APP and presenilin genes, causes rare forms of Alzheimer's disease (AD). These genetic changes have been proposed to cause AD by elevating levels of amyloid-beta peptides (Abeta), which are thought to be neurotoxic. Since overexpression of APP also causes defects in axonal transport, we tested whether defects in axonal transport were the result of Abeta poisoning of the axonal transport machinery. Because directly varying APP levels also alters APP domains in addition to Abeta, we perturbed Abeta generation selectively by combining APP transgenes in Drosophila and mice with presenilin-1 (PS1) transgenes harboring mutations that cause familial AD (FAD). We found that combining FAD mutant PS1 with FAD mutant APP increased Abeta42/Abeta40 ratios and enhanced amyloid deposition as previously reported. Surprisingly, however, this combination suppressed rather than increased APP-induced axonal transport defects in both Drosophila and mice. In addition, neuronal apoptosis induced by expression of FAD mutant human APP in Drosophila was suppressed by co-expressing FAD mutant PS1. We also observed that directly elevating Abeta with fusions to the Familial British and Danish Dementia-related BRI protein did not enhance axonal transport phenotypes in APP transgenic mice. Finally, we observed that perturbing Abeta ratios in the mouse by combining FAD mutant PS1 with FAD mutant APP did not enhance APP-induced behavioral defects. A potential mechanism to explain these findings was suggested by direct analysis of axonal transport in the mouse, which revealed that axonal transport or entry of APP into axons is reduced by FAD mutant PS1. Thus, we suggest that APP-induced axonal defects are not caused by Abeta.
AI snapshot
Written from the paper’s full text.
TL;DR
Combining FAD mutant presenilin-1 with FAD mutant APP increased Aβ42/Aβ40 ratios and amyloid deposition but suppressed, rather than enhanced, APP-induced axonal transport defects in Drosophila and mice. The authors conclude that APP-induced axonopathies are not caused by Aβ peptides.
Key findings
- In 4-month-old mice, single transgenic Tg-swAPP PrP had significantly higher percentages of ChAT-IR fibers with large varicosities in the basal nucleus (2.7–3.6, 3.6–4.5, and >4.5 µm) and sensory cortex (1.4–2.0, 2.0–2.6, and >2.6 µm) than WT, whereas double transgenic Tg-swAPP PrP;Tg-A246EPS1 PrP showed no differences from WT in either genetic background.
- BRI-Aβ40 or BRI-Aβ42 fusions dramatically altered Aβ levels—e.g., 10–11-month-old Tg-swAPP PrP;Tg-BRI-Aβ42 PrP had 24,499.67 ± 4,841.7 fmol/mg Aβ40 and 9,394.67 ± 2,554.19 fmol/mg Aβ42 versus 2,935.4 ± 575.35 and 1,561.2 ± 166.76 fmol/mg in Tg-swAPP PrP—but did not change the frequency of axonal pathology.
- In Drosophila, co-expression of FAD mutant presenilin PsnE280A with FAD mutant APP suppressed APP-induced axonal blockages and TUNEL-positive apoptotic neurons.
- FAD mutant PS1 did not enhance APP-induced behavioral deficits; it partially suppressed rotarod deficits, and Tg-swAPP PrP but not Tg-swAPP PrP;Tg-A246EPS1 PrP mice showed cued conditioning deficits versus WT. Sciatic nerve ligation suggested FAD mutant PS1 reduced anterograde axonal transport of APP.
Methods
- Transgenic mouse crosses: Tg-swAPP PrP × Tg-A246EPS1 PrP in C57BL/6J/C3H/HeJ and C57BL/6J backgrounds, examined at 4 months unless otherwise stated; Tg-swAPP PrP × BRI-Aβ40 or BRI-Aβ42 mice examined at 10–11 months. Drosophila used APPL-GAL4 with UAS-SWE and/or UAS-PsnE280A.
- Outcomes included blinded ChAT immunohistochemistry and immuno-electron microscopy of basal nucleus and sensory cortex, Drosophila CSP immunofluorescence and TUNEL, behavioral battery (open field, rotarod, fear conditioning), sciatic nerve ligation with western blotting, and Aβ ELISAs.
- Statistics used Kruskal–Wallis non-parametric ANOVA and Mann–Whitney U-test, or ANOVA with Scheffe’s post hoc test, at P < 0.05.
Limitations
- Stated in the paper: WT samples could not be analyzed in the BRI mouse histology owing to poor staining quality; the authors state that further work is necessary to discriminate between possible mechanisms.
- Evident from the text: conclusions rely on transgenic Drosophila and mouse models rather than human AD tissue, and the mechanism by which FAD mutant PS1 suppresses APP-induced phenotypes is not established.
- Evident from the text: some histology groups were small (e.g., n = 3 per genotype in Fig. 1D; n = 5 per Drosophila group), and several behavioral effects were partial or mild rather than absent.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
3 of 37 cited sources checked · 2 supported · 1 flagged · accuracy not yet measured
- Premisecitation
Increasing Aβ by expressing FAD mutant PS1 together with FAD mutant APP failed to produce substantial enhancements of the behavioral deficits observed in mice overexpressing FAD mutant APP alone.
“Our findings are also consistent with research showing that increasing Ab by expressing FAD mutant PS1 together with FAD mutant APP failed to produce substantial enhancements of the behavioral deficits observed in mice overexpressing FAD mutant APP alone (56)(57)(58).”
Quote in the paperSubstantial claim1 of 3 sources checked- cites [56] Dineley, 2002, Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins, J. Biol. Chem. source
The Discussion (page not provided) says the contextual fear-learning deficit was more pronounced in PS-1/APP mice, contrary to the claim that adding mutant PS-1 failed to substantially enhance the behavioral deficit. The reported comparison at five months also found that APP-only mice performed significantly better than PS-1/APP mice after more intensive training. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured - cites [57] Holcomb, 1998, Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes, Nat. Med. source
- cites [58] Holcomb, 1999, Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits, Behav. Genet. source
- Findingown data
In 4-month-old Tg-swAPP Prp mice, the increase in APP accumulation at the proximal ligature site was less than in WT.
“In 4-month-old Tg-swAPP Prp mice, although we observed an increase in APP accumulation at the proximal ligature site, the extent was less than in WT, suggesting a reduction in the anterograde axonal transport of APP upon its overexpression.”
Quote in the paperSubstantial claim - Findingown data
Expression of PsnE280A alone had no obvious effect on axonal phenotypes.
“Note that the expression of PsnE280A alone had no obvious effect on axonal phenotypes.”
Quote in the paperSubstantial claim - Findingown data
Expression of the Swedish mutant of APP in combination with PsnE280A failed to induce axonal blockages in Drosophila larval segmental nerves.
“Strikingly, expression of the Swedish mutant of APP in combination with PsnE280A (Fig. 2A and B) failed to induce axonal blockages.”
Quote in the paperSubstantial claim - Findingown data
Combining FAD mutant PS1 with FAD mutant APP suppressed rather than increased APP-induced axonal transport defects in both Drosophila and mice.
“Surprisingly, however, this combination suppressed rather than increased APP-induced axonal transport defects in both Drosophila and mice.”
Quote in the paperSubstantial claim
- Findingown data
Tg-swAPP Prp mice exhibited early changes in contextual conditioning that are not enhanced, and may even be mildly suppressed, by expression of FAD mutant PS1.
“When compared to WT, Tg-A246EPS1 Prp and Tg-swAPP Prp ; Tg-A246EPS1 Prp littermates in two genetic backgrounds (C57BL/6J/C3H/HeJ and C57BL/6J), Tg-swAPP Prp mice exhibited early changes in contextual conditioning that are not enhanced, and may even be mildly suppressed by expression of FAD mutant PS1”
Quote in the paperSubstantial claim - Findingown data
Perturbing Aβ ratios in the mouse by combining FAD mutant PS1 with FAD mutant APP did not enhance APP-induced behavioral defects.
“Finally, we observed that perturbing Ab ratios in the mouse by combining FAD mutant PS1 with FAD mutant APP did not enhance APP-induced behavioral defects.”
Quote in the paperSubstantial claim - Findingown data
At the sensory cortex, only Tg-swAPP Prp mice contained a significantly increased percentage of ChAT-IR fibers having varicosities of diameters between 1.4 and 2.0 microns, 2.0 and 2.6 microns and larger than 2.6 microns compared with WT, Tg-A246EPS1 Prp and double transgenic littermates.
“Again, however, only Tg-swAPP Prp mice contained significantly increased percentage of ChAT-IR fibers having varicosities of diameters between 1.4 and 2.0 microns, 2.0 and 2.6 microns and larger than 2.6 microns compared with WT, Tg-A246EPS1 Prp and Tg-swAPP Prp ; Tg-A246EPS1 Prp littermates”
Quote in the paperSubstantial claim - Findingown data
In 4-month-old WT mice, there was a significant increase in the levels of APP in the proximal and distal stumps in the ligated compared with unligated sciatic nerves.
“In 4-month-old WT mice, we observed a significant increase in the levels of APP in the proximal and distal stumps in the ligated compared with unligated sciatic nerves (Fig. 4A and B).”
Quote in the paperSubstantial claim - Findingown data
Axonal transport or entry of APP into axons is reduced by FAD mutant PS1 in the mouse.
“A potential mechanism to explain these findings was suggested by direct analysis of axonal transport in the mouse, which revealed that axonal transport or entry of APP into axons is reduced by FAD mutant PS1.”
Quote in the paperSubstantial claim - Findingown data
Increasing Aβ in animals expressing FAD APP does not enhance axonal defects.
“Our observation that increasing Ab in animals expressing FAD APP does not enhance axonal defects, coupled to other reports, raise the possibility that the total amount or character of proteolytic processing of APP to Ab is not the primary driver of detrimental phenotypic changes in axons.”
Quote in the paperSubstantial claim - Findingown data
Double transgenic Tg-swAPP Prp; Tg-A246EPS1 Prp animals, which have perturbed Aβ generation, particularly increased Aβ42, have less severe axonal phenotypes than single transgenic Tg-swAPP Prp animals.
“Taken together, however, and contrary to expectation, these data reveal that double transgenic Tg-swAPP Prp ; Tg-A246EPS1 Prp animals, which have perturbed Ab generation, particularly increased Ab42, have less severe axonal phenotypes than single transgenic Tg-swAPP Prp animals.”
Quote in the paperSubstantial claim - Findingown data
Neuronal apoptosis induced by expression of FAD mutant human APP in Drosophila was suppressed by co-expressing FAD mutant PS1.
“In addition, neuronal apoptosis induced by expression of FAD mutant human APP in Drosophila was suppressed by co-expressing FAD mutant PS1.”
Quote in the paperSubstantial claim - Findingown data
ChAT-IR profiles of large diameters containing numerous haphazardly distributed vesicles and mitochondria were identified almost exclusively in Tg-swAPP Prp, but not in WT and double transgenic littermates.
“ChAT-IR profiles of large diameters containing numerous haphazardly distributed vesicles and mitochondria were identified almost exclusively in Tg-swAPP Prp , but not in WT and Tg-swAPP Prp ; Tg-A246EPS1 Prp , littermates”
Quote in the paperSubstantial claim - Findingown data
There were no differences in the percentage of ChAT-IR fibers with varicosities in any of the diameter intervals when double transgenic Tg-swAPP Prp; Tg-A246EPS1 Prp were compared to WT littermates in either genetic background.
“To our surprise, however, there were no differences in the percentage of ChAT-IR fibers with varicosities in any of the diameter intervals when double transgenic Tg-swAPP Prp ; Tg-A246EPS1 Prp were compared to WT littermates in either of the genetic backgrounds.”
Quote in the paperSubstantial claim - Findingown data
There was no change in the amount of kinesin-I associated with brain-derived membrane preparations either by flotation or by differential centrifugation between WT and Tg-A246EPS1 Prp littermates.
“We observed no change in the amount of kinesin-I associated with brain-derived membrane preparations either by flotation or by differential centrifugation between WT and Tg-A246EPS1 Prp littermates (data not shown).”
Quote in the paperSubstantial claim - Findingown data
Tg-swAPP Prp; Tg-BRI-Aβ42 Prp littermates had 24499.67+4841.7 and 9394.67+2554.19 fmols/mg of wet brain formic acid extractable Aβ40 and Aβ42, respectively.
“while Tg-swAPP Prp ; Tg-BRI-Ab42 Prp littermates had 24499.67+ 4841.7 and 9394.67 + 2554.19 fmols/mg of wet brain formic acid extractable Ab40 and Ab42, respectively.”
Quote in the paperSubstantial claim - Findingown data
Single transgenic Tg-A246EPS1 Prp mice displayed a slight elevation in the percentage of ChAT-IR fibers with large diameter varicosities in the 2.7-3.6 mm category compared with WT littermates in the C57BL/6J genetic background.
“Single transgenic Tg-A246EPS1 Prp mice displayed a slight elevation in the percentage of ChAT-IR fibers with large diameter varicosities in the 2.7-3.6 mm category compared with WT littermates in the C57BL/6J genetic background.”
Quote in the paperNot a substantial claim - Findingown data
Tg-swAPP PrP mice exhibited a substantial deficit on the rotarod compared to WT mice or mice in which FAD mutant PS1 was expressed on its own.
“When tested on the rotarod (Fig. 3A), Tg-swAPP PrP mice exhibited a substantial deficit compared to WT mice or mice in which FAD mutant PS1 was expressed on its own.”
Quote in the paperSubstantial claim - Findingown data
Directly elevating Aβ with fusions to the Familial British and Danish Dementia-related BRI protein did not enhance axonal transport phenotypes in APP transgenic mice.
“We also observed that directly elevating Ab with fusions to the Familial British and Danish Dementia-related BRI protein did not enhance axonal transport phenotypes in APP transgenic mice.”
Quote in the paperSubstantial claim - Findingcitation
Single transgenic Tg-swAPP Prp mice had a significantly higher percentage of ChAT-IR fibers with varicosities having diameters between 2.7 and 3.6 mm, 3.6 and 4.5 mm and larger than 4.5 mm compared with WT littermates in both genetic backgrounds examined.
“As reported previously (7), single transgenic Tg-swAPP Prp mice had a significantly higher percentage of choline acetyltransferase-immunoreactive (ChAT-IR) fibers with varicosities having diameters between 2.7 and 3.6 mm, 3.6 and 4.5 mm and larger than 4.5 mm compared with WT littermates in both genetic backgrounds examined”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [7] Stokin, 2005, Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease, Science source
- Findingown data
There is no significant difference in the percentage of cholinergic fibers in the BN with varicosities of diameters 1.8-2.7 mm, 2.7-3.6 mm, 3.6-4.5 mm, and over 4.5 mm between 10-11-month-old Tg-swAPP PrP mice and Tg-BRI-Ab40, Tg-BRI-Ab42, Tg-swAPP PrP;BRI-Ab40, and Tg-swAPP PrP;BRI-Ab42 littermates.
“(E) No significant difference in the percentage of cholinergic fibers in the BN with varicosities of diameters between 1.8 and 2.7 mm, 2.7-3.6 mm, 3.6-4.5 and over 4.5 mm between 10-and 11-month-old Tg-swAPP PrP (n ¼ 6) and Tg-BRI-Ab40 Prp (n ¼ 3), Tg-BRI-Ab42 Prp (n ¼ 5), Tg-swAPP PrP ; BRI-Ab40 Prp (n ¼ 4) and Tg-swAPP PrP ; BRI-Ab42 Prp (n ¼ 4) littermates.”
Quote in the paperSubstantial claim - Findingown data
Average levels of APP in the proximal stump of ligated sciatic nerves are significantly reduced in 4-month-old Tg-A246EPS1 PrP mice compared with WT littermates.
“(C) Representative image (a) of significantly reduced average levels of APP (b) in the proximal stump of ligated sciatic nerves in 4-month-old Tg-A246EPS1 PrP (blue; n ¼ 6) compared with WT (black; n ¼ 6) littermates (P 0.05).”
Quote in the paperSubstantial claim - Findingown data
Mutant PS1 suppresses APP-induced axonal swellings or blockages in the baso-cortical cholinergic fibers of mice.
“Mutant PS1 suppresses APP-induced axonal swellings or blockages in the baso-cortical cholinergic fibers of mice.”
Quote in the paperSubstantial claim - Findingown data
There is no difference in time spent on the rotating rod between WT and Tg-A246EPS1 PrP mice in either genetic background.
“No difference in the time spent on the rotating rod between WT and Tg-A246EPS1 PrP (n ¼ 11 and 15) mice in either of the genetic backgrounds.”
Quote in the paperSubstantial claim - Findingown data
Average levels of APP were significantly increased after 6 h of ligation relative to unligated controls in the proximal stump of 4-month-old WT, Tg-swAPP PrP, Tg-A246EPS1 PrP, and Tg-swAPP PrP;Tg-A246EPS1 PrP mice.
“Average levels of APP were significantly increased after 6 h of ligation relative to unligated controls in the proximal stump of 4-month-old WT (n ¼ 6, P 0.005), Tg-swAPP PrP (n ¼ 7, P 0.005), Tg-A246EPS1 PrP (n ¼ 6, P 0.000005) and Tg-swAPP PrP ; Tg-A246EPS1 PrP (n ¼ 7, P 0.005)”
Quote in the paperNot a substantial claim - Findingown data
Tg-swAPP PrP and Tg-swAPP PrP;Tg-A246EPS1 PrP mice show a significant decrease in time spent on the rotating rod compared with WT littermates in both C57BL/6J/C3H/HeJ and C57BL/6J genetic backgrounds.
“(A) Significant decrease in the time spent on the rotating rod by Tg-swAPP PrP (n ¼ 9 and 17, Ã means P 0.05) and Tg-swAPP PrP ; Tg-A246EPS1 PrP (n ¼ 7 and 17, Ã means P 0.05) mice on trial days 1, 3, 5 and 8 and on trial day 8, respectively, in the C57BL/6J/C3H/HeJ (a) and on trial days 1, 3 and 8 and on trial days 1 and 3, respectively, in the C57BL/6J (b) genetic background compared with WT (n”
Quote in the paperSubstantial claim - Findingown data
Average levels of APP in the proximal stump of ligated sciatic nerves are significantly reduced in 4-month-old Tg-swAPP PrP;Tg-A246EPS1 PrP mice compared with Tg-swAPP PrP littermates.
“(D) Representative image (a) of significantly reduced average levels of APP (b) in the proximal stump of ligated sciatic nerves in 4-month-old Tg-swAPP PrP ; Tg-A246EPS1 PrP (green; n ¼ 7) compared with Tg-swAPP PrP (red; n ¼ 7) littermates (P 0.05).”
Quote in the paperSubstantial claim - Findingown data
There is no difference in the percentage of freezing between WT, Tg-swAPP PrP, Tg-A246EPS1 PrP, and Tg-swAPP PrP;Tg-A246EPS1 PrP littermates during fear conditioning training in both genetic backgrounds.
“(B) No difference in the percentage of freezing between WT (n ¼ 11 and 19), Tg-swAPP PrP (n ¼ 9 and 17), Tg-A246EPS1 PrP (n ¼ 11 and 15) and Tg-swAPP PrP ; Tg-A246EPS1 PrP (n ¼ 7 and 17) littermates during fear conditioning training (a and b) in C57BL/6J/C3H/HeJ (a) and C57BL/6J (b) genetic backgrounds.”
Quote in the paperNot a substantial claim - Findingown data
In 4-month-old WT mice, 6 h ligation of the sciatic nerve produced significant accumulation of APP in its proximal and distal stumps, but not in the dorsal root ganglion.
“In 4-month-old WT mice 6 h ligation of the sciatic nerve produced significant accumulation of APP in its proximal and distal stumps, but not in the dorsal root ganglion.”
Quote in the paperSubstantial claim - Findingown data
Mutant PS1 reduces axonal transport of APP in mice.
“Mutant PS1 reduces axonal transport of APP in mice.”
Quote in the paperSubstantial claim - Findingown data
FAD mutant Drosophila presenilin suppresses FAD mutant APP-induced axonal blockages in the segmental projection neurons of Drosophila larvae.
“FAD mutant Drosophila presenilin suppresses FAD mutant APP-induced axonal blockages in the segmental projection neurons of Drosophila larvae.”
Quote in the paperSubstantial claim - Findingown data
Mutant PS1 suppresses APP-induced behavioral impairments in mice.
“Mutant PS1 suppresses APP-induced behavioral impairments in mice.”
Quote in the paperSubstantial claim - Interpretationown data
FAD mutant presenilin can suppress apoptosis induced by FAD mutant APP.
“Thus, it appears that FAD mutant presenilin can suppress apoptosis induced by FAD mutant APP.”
Quote in the paperSubstantial claim - Interpretationown data
The total amount or character of proteolytic processing of APP to Aβ is not the primary driver of detrimental phenotypic changes in axons.
“Our observation that increasing Ab in animals expressing FAD APP does not enhance axonal defects, coupled to other reports, raise the possibility that the total amount or character of proteolytic processing of APP to Ab is not the primary driver of detrimental phenotypic changes in axons.”
Quote in the paperSubstantial claim - Interpretationown data
FAD mutant presenilin suppressed, rather than enhanced, the formation of axonal blockages caused by FAD mutant APP.
“This observation suggested that, as in the mouse, FAD mutant presenilin suppressed, rather than enhanced the formation of axonal blockages caused by FAD mutant APP.”
Quote in the paperSubstantial claim - Interpretationown data
The reduced APP accumulation at the proximal ligature site in Tg-swAPP Prp mice suggests a reduction in the anterograde axonal transport of APP upon its overexpression.
“In 4-month-old Tg-swAPP Prp mice, although we observed an increase in APP accumulation at the proximal ligature site, the extent was less than in WT, suggesting a reduction in the anterograde axonal transport of APP upon its overexpression.”
Quote in the paperSubstantial claim - Interpretationown data
Aβ is not the only APP- or PS1-related insult that can induce axonal transport deficits and produce neuronal changes.
“We conclude that Ab is not the only APP-or PS1-related insult that can induce axonal transport deficits and produce neuronal changes.”
Quote in the paperSubstantial claim - Interpretationreasoning
Expression of FAD mutant APP with FAD mutant PS1 may operate additively in reducing anterograde axonal transport of APP.
“Intriguingly, expression of FAD mutant APP with FAD mutant PS1 may operate additively in reducing anterograde axonal transport of APP.”
Quote in the paperNot a substantial claim - Interpretationown data
APP-induced axonal defects are not caused by Aβ.
“Thus, we suggest that APP-induced axonal defects are not caused by Ab.”
Quote in the paperSubstantial claim - Premisecitation
Overexpression of WT APP or APP bearing FAD mutations in Drosophila and mice can cause impaired axonal transport and axonal defects.
“Intriguingly, recent work revealed that overexpression of WT APP or APP bearing FAD mutations in Drosophila and mice can cause impaired axonal transport and axonal defects (7,8,29,30).”
Quote in the paperSubstantial claim0 of 4 sources checked- cites [7] Stokin, 2005, Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease, Science source
- cites [8] Salehi, 2006, Increased App expression in a mouse model of Down’s syndrome disrupts NGF transport and causes cholinergic neuron degeneration, Neuron source
- cites [29] Gunawardena, 2001, Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila, Neuron source
- cites [30] Torroja, 1999, Neuronal overexpression of APPL, the Drosophila homologue of the amyloid precursor protein (APP), disrupts axonal transport, Curr. Biol. source
- Premisecitation
Human Ab40 or Ab42 peptides are not needed to generate NGF transport deficits.
“and that human Ab40 or Ab42 peptides are not needed to generate NGF transport deficits”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [8] Salehi, 2006, Increased App expression in a mouse model of Down’s syndrome disrupts NGF transport and causes cholinergic neuron degeneration, Neuron source
- Interpretationreasoning
In many experiments in addition to ours, levels of proteolytic processing of APP to Ab peptides such as Ab42 are not well correlated with the development of a number of cellular and behavioral deficits.
“Thus, in many experiments in addition to ours, levels of proteolytic processing of APP to Ab peptides such as Ab42 are not well correlated with the development of a number of cellular and behavioral deficits.”
Quote in the paperSubstantial claim - Premisecitation
Expression of the Swedish mutant of APP could induce apoptosis in Drosophila larval neurons.
“In previous work (29), we found that the expression of the Swedish mutant of APP could induce apoptosis in Drosophila larval neurons.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [29] Gunawardena, 2001, Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila, Neuron source
- Premisecitation
NGF transport deficits can be caused by overexpression of APP.
“The results suggest that NGF transport deficits can be caused by overexpression of APP”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [8] Salehi, 2006, Increased App expression in a mouse model of Down’s syndrome disrupts NGF transport and causes cholinergic neuron degeneration, Neuron source
- Interpretationcitation
Our data are consistent with a recent report about transgenic mice overexpressing APP which lack a caspase cleavage site in the C-terminal cytoplasmic region of APP.
“Finally, our data are consistent with a recent report about transgenic mice overexpressing APP which lack a caspase cleavage site in the C-terminal cytoplasmic region of APP.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [63] Galvan, 2006, Reversal of Alzheimer’s-like pathology and behavior in human APP transgenic mice by mutation of Asp664, Proc. Natl Acad. Sci. USA source
- Premisecitation
Increasing human Ab42 levels may minimally enhance NGF transport deficits caused by APP overexpression.
“although increasing human Ab42 levels may minimally enhance NGF transport deficits caused by APP overexpression.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [8] Salehi, 2006, Increased App expression in a mouse model of Down’s syndrome disrupts NGF transport and causes cholinergic neuron degeneration, Neuron source
- Premisecitation
In both Drosophila and mice, APP-mediated axonal transport defects can be enhanced by genetic reductions in kinesin-I.
“In fact, in both Drosophila and mice, APP-mediated axonal transport defects can be enhanced by genetic reductions in kinesin-I (7,29,30).”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [7] Stokin, 2005, Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease, Science source
- cites [29] Gunawardena, 2001, Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila, Neuron source
- cites [30] Torroja, 1999, Neuronal overexpression of APPL, the Drosophila homologue of the amyloid precursor protein (APP), disrupts axonal transport, Curr. Biol. source
- Premisecitation
Expression of human APP carrying the Swedish FAD mutation caused axonal blockages within larval segmental nerves.
“In previous work, we found that the expression of human APP carrying the Swedish FAD mutation caused axonal blockages within larval segmental nerves (29).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [29] Gunawardena, 2001, Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila, Neuron source
- Classified as probably not a substantial claim. 22
- May combine two claims. 34
- The quote only partly states this claim. 2
Classified as probably not a substantial claim.
PremisecitationOverexpression of WT and FAD mutant human APP and Drosophila APPL in the Drosophila larval nervous system causes axonal blockages reminiscent of those found in mutants for molecular motors.
“Previous work showed that overexpression of WT and FAD mutant human APP and Drosophila APPL in the Drosophila larval nervous system causes axonal blockages reminiscent of those found in mutants for molecular motors (29,30,50).”
Quote in the paperSubstantial claim1 of 3 sources checked- cites [29] Gunawardena, 2001, Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila, Neuron source
- cites [30] Torroja, 1999, Neuronal overexpression of APPL, the Drosophila homologue of the amyloid precursor protein (APP), disrupts axonal transport, Curr. Biol. source
- cites [50] Hurd, 1996, Kinesin mutations cause motor neuron disease phenotypes by disrupting fast axonal transport in Drosophila, Genetics source
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationThe density of cortical cholinergic synapses has been shown to increase in mice overexpressing FAD mutant APP and decreased in mice expressing FAD mutant APP combined with FAD mutant PS1.
“Similarly, the density of cortical cholinergic synapses has been shown to increase in mice overexpressing FAD mutant APP and decreased in mice expressing FAD mutant APP combined with FAD mutant PS1 (52).”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [52] Wong, 1999, Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes, J. Neurosci. source
May combine two claims.
Findingown dataData collected by either observer revealed comparable percentages of fibers with varicosities in all diameter intervals examined among Tg-swAPP Prp, Tg-BRI-Aβ40 Prp and Tg-BRI-Aβ42 Prp and no differences among Tg-swAPP Prp, Tg-swAPP Prp; Tg-BRI-Aβ40 Prp and Tg-swAPP Prp; Tg-BRI-Aβ42 Prp littermates despite dramatic changes in Aβ levels and amyloid deposition.
“Data collected by either of the observers revealed comparable percentages of fibers with varicosities in all of the diameter intervals examined among Tg-swAPP Prp , Tg-BRI-Ab40 Prp and Tg-BRI-Ab42 Prp and no differences in the percentage of fibers with varicosities in any of the diameter intervals among Tg-swAPP Prp , Tg-swAPP Prp ; Tg-BRI-Ab40 Prp and Tg-swAPP Prp ; Tg-BRI-Ab42 Prp littermates”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataTUNEL-positive neurons were observed in animals expressing FAD mutant APP alone, but not in combination with FAD mutant presenilin.
“We observed TUNEL-positive neurons in animals expressing FAD mutant APP alone, but not in combination with FAD mutant presenilin (Fig. 2C and D).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThe length of cholinergic fibers per field at their termini was significantly increased in Tg-swAPP Prp and significantly decreased in double transgenic Tg-swAPP Prp; Tg-A246EPS1 Prp compared with WT and Tg-A246EPS1 Prp littermates.
“Surprisingly, in contrast to fibers in the BN, we found that the length of cholinergic fibers per field at their termini was significantly increased in Tg-swAPP Prp and significantly decreased in Tg-swAPP Prp ; Tg-A246EPS1 Prp compared with WT and Tg-A246EPS1 Prp littermates”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataAll of these transgenic mice except for Tg-BRI-Aβ40 Prp exhibited amyloid deposition, with Tg-swAPP Prp; Tg-BRI-Aβ42 Prp demonstrating the most extensive amyloid deposition.
“All of these transgenic mice except for Tg-BRI-Ab40 Prp exhibited amyloid deposition with Tg-swAPP Prp ; Tg-BRI-Ab42 Prp demonstrating the most extensive amyloid deposition.”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataAlthough expressing FAD mutant PS1 with overexpression of FAD mutant APP enhances Aβ42 production and amyloid deposition, it suppresses axonal defects and gives mild suppression, as opposed to enhancement, of other defects such as behavior.
“In conclusion, it is surprising that although expressing FAD mutant PS1 with overexpression of FAD mutant APP enhances Ab42 production and amyloid deposition, it suppresses axonal defects and gives mild suppression, as opposed to enhancement of other defects such as behavior.”
Quote in the paperSubstantial claimMay combine two claims.
FindingcitationTg-swAPP Prp commonly exhibited axonal blockages that were not immunoreactive for ChAT and occasionally displayed electron dense axoplasm reminiscent of axonal degeneration.
“As previously reported (7), Tg-swAPP Prp commonly exhibited axonal blockages that were not immunoreactive for ChAT and occasionally displayed electron dense axoplasm reminiscent of axonal degeneration”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [7] Stokin, 2005, Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease, Science source
May combine two claims.
Findingown dataCombining FAD mutant PS1 with FAD mutant APP increased Aβ42/Aβ40 ratios and enhanced amyloid deposition.
“We found that combining FAD mutant PS1 with FAD mutant APP increased Ab42/Ab40 ratios and enhanced amyloid deposition as previously reported.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown data10-11-month-old Tg-swAPP Prp mice had 2935.4+575.35 and 1561.2+166.76 fmols/mg of wet brain of formic acid extractable Aβ40 and Aβ42, respectively.
“Specifically, 10-11-month-old Tg-swAPP Prp mice had 2935.4+ 575.35 and 1561.2 + 166.76 fmols/mg of wet brain of formic acid extractable Ab40 and Ab42, respectively.”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataCo-expression of FAD mutant PS1 with FAD mutant APP failed to enhance the rotarod deficit seen in Tg-swAPP PrP mice, and actually produced partial suppression of the working performance deficit.
“Strikingly, not only did co-expression of FAD mutant PS1 with FAD mutant APP fail to enhance the deficit seen in Tg-swAPP PrP mice, but it actually produced partial suppression of the working performance deficit seen in Tg-swAPP Prp mice.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataTg-swAPP Prp; Tg-BRI-Aβ40 Prp littermates had 603+161.41 and 266.5+129.93 fmols/mg of wet brain formic acid extractable Aβ40 and Aβ42, respectively.
“Tg-swAPP Prp ; Tg-BRI-Ab40 Prp littermates had 603 + 161.41 and 266.5 + 129.93 fmols/mg of wet brain formic acid extractable Ab40 and Ab42, respectively”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataTg-swAPP Prp, but not Tg-A246EPS1 Prp or double transgenic mice, exhibited deficits in cued conditioning compared to WT littermates, suggesting these behavioral phenotypes were not enhanced by increasing Aβ generation.
“Tg-swAPP Prp , but not Tg-A246EPS1 Prp or Tg-swAPP Prp ; Tg-A246EPS1 Prp , mice exhibited deficits in conditioning compared to WT littermates, suggesting that these behavioral phenotypes were not enhanced by increasing Ab generation.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataCSP-immunoreactive axonal blockages are observed in larvae overexpressing FAD mutant human APP (SWE), but not in larvae expressing FAD mutant Drosophila presenilin (PsnE280A) or in larvae co-expressing FAD mutant Drosophila presenilin with FAD mutant APP (PsnE280A;SWE).
“(A) Cysteine string protein-immunoreactive (CSP) axonal blockages are observed (arrows) in larvae overexpressing FAD mutant human APP (SWE, n ¼ 5), but not in larvae expressing FAD mutant Drosophila presenilin (PsnE280A, n ¼ 5) or in larvae co-expressing FAD mutant Drosophila presenilin with FAD mutant APP (PsnE280A;SWE, n ¼ 5, bar¼10 mm).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataAverage levels of APP were significantly increased after 6 h of ligation relative to unligated controls in the distal stump of 4-month-old WT and Tg-swAPP PrP mice, but not in Tg-A246EPS1 PrP and Tg-swAPP PrP;Tg-A246EPS1 PrP mice.
“and in the distal stump of 4-month-old WT (n ¼ 6, P 0.05) and Tg-swAPP PrP (n ¼ 7, P 0.05), but not Tg-A246EPS1 PrP (n ¼ 6) and Tg-swAPP PrP ; Tg-A246EPS1 PrP (n ¼ 7).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataTUNEL analysis indicates apoptotic nuclei in larval brains expressing FAD mutant APP (SWE), but not in larval brains expressing FAD mutant Drosophila presenilin (PsnE280A) or in larval brains co-expressing FAD mutant Drosophila presenilin with FAD mutant APP (PsnE280A;SWE).
“(C) TUNEL analysis indicates apoptotic nuclei in larval brains expressing FAD mutant APP (SWE, n ¼ 5, arrows), but not in larval brains expressing FAD mutant Drosophila presenilin (PsnE280A, n ¼ 5) or in larval brains co-expressing FAD mutant Drosophila presenilin with FAD mutant APP (PsnE280A;SWE, n ¼ 5, bar¼10 mm).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThe percentage of cholinergic fibers in deep layers of the SC with varicosities of diameters 1.4-2.0 mm and 2.0-2.6 mm is increased in Tg-swAPP PrP mice, but not in WT, Tg-A246EPS1 PrP, or Tg-swAPP PrP;Tg-A246EPS1 PrP mice.
“(b) Increased percentage of cholinergic fibers in deep layers of the SC with varicosities of diameters between 1.4 and 2.0 mm and 2.0 and 2.6 (swellings) in Tg-swAPP PrP (n ¼ 3, Ã means P 0.05), but not WT (n ¼ 3), Tg-A246EPS1 PrP (n ¼ 3) or Tg-swAPP PrP ; Tg-A246EPS1 PrP mice (n ¼ 3).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThe percentage of cholinergic fibers in BN with varicosities of diameters 2.7-3.6 mm, 3.6-4.5 mm, and over 4.5 mm is increased in Tg-swAPP PrP mice, and with varicosities of 2.7-3.6 mm in Tg-A246EPS1 PrP mice, but not in WT or Tg-swAPP PrP;Tg-A246EPS1 PrP mice.
“(D) (a) Increased percentage of cholinergic fibers in BN with varicosities of diameters between 2.7 and 3.6 mm, 3.6 and 4.5 mm and over 4.5 mm (swellings) in Tg-swAPP PrP (n ¼ 3, Ã means P 0.05) and between 2.7 and 3.6 mm (swellings) in Tg-A246EPS1 PrP (n ¼ 3, Ã means P 0.05), but not WT (n ¼ 3) or Tg-swAPP PrP ; Tg-A246EPS1 PrP mice (n ¼ 3).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataAxonal blockages in baso-cortical cholinergic profiles are present in Tg-swAPP PrP and Tg-A246EPS1 PrP mice, but not in WT or Tg-swAPP PrP;Tg-A246EPS1 PrP mice.
“Representative electron microscope images of cholinergic profiles in BN showing axonal blockages in Tg-swAPP PrP (b) and Tg-A246EPS1 PrP (c), but not WT (a) or Tg-swAPP PrP ; Tg-A246EPS1 PrP (d) mice; axonal profiles are circled in red (bar 300 nm).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataIn deep layers of the SC, cholinergic fiber swellings are present in Tg-swAPP PrP mice, to a lesser extent in Tg-A246EPS1 PrP and Tg-swAPP PrP;Tg-A246EPS1 PrP mice, but not in WT mice.
“Representative light microscope images of cholinergic fibers in deep layers of the SC showing swellings (red arrows) in Tg-swAPP PrP (b), to a lesser extent in Tg-A246EPS1 PrP (c) and Tg-swAPP PrP ; Tg-A246EPS1 PrP (d), but not in WT (a) mice (bar 15 mm).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataDuring evaluation of cued conditioning 24 h after training, the percentage of freezing is significantly reduced in Tg-swAPP PrP mice, but not in Tg-A246EPS1 PrP or Tg-swAPP PrP;Tg-A246EPS1 PrP mice, compared with WT littermates in both genetic backgrounds.
“Significantly reduced percentage of freezing in Tg-swAPP PrP ( Ã means P 0.05), but not Tg-A246EPS1 PrP or Tg-swAPP PrP ; Tg-A246EPS1 PrP , compared with WT littermates during evaluation of cued conditioning 24 h after training (c and d) in C57BL/6J/C3H/HeJ (c) and C57BL/ 6J (d) genetic backgrounds.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataLarge axonal swellings in baso-cortical cholinergic fibers are seen primarily in Tg-swAPP PrP mice, but not in WT, Tg-A246EPS1 PrP, or Tg-swAPP PrP;Tg-A246EPS1 PrP littermates.
“Representative light microscope images of cholinergic fibers in BN showing varicosities (black arrows) in all genotypes, while large axonal swellings (red arrows) were seen primarily in Tg-swAPP PrP (b), but not WT (a), Tg-A246EPS1 PrP (c) or Tg-swAPP PrP ; Tg-A246EPS1 PrP (d) littermates (bar 15 mm).”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenAxonal transport in sciatic nerve ligation experiments was scanned by one investigator, then coded for genotypes and analyzed blind by another investigator who broke the codes only upon completion of the experiments.
“Axonal transport was evaluated in sciatic nerve ligation experiments in which gels and western blots were run and scanned by one investigator, then coded for genotypes and analyzed 'blind' by another investigator who broke the codes only upon completion of the experiments.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningEither the cellular location of APP processing, or the axonal defects generated by APP overexpression, are the major causes of neuronal and behavioral defects seen in mice overexpressing mutant APP.
“Instead, we suggest that either the cellular location of APP processing, or the axonal defects generated by APP overexpression are the major causes of neuronal and behavioral defects seen in mice overexpressing mutant APP.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataExpression of FAD mutant PS1 reduces the fast anterograde axonal transport of endogenous and transgenic APP, in addition to increasing Aβ42 generation.
“Collectively, these results suggest that, in addition to increasing Ab42 generation (Supplementary Material, Fig. S10), expression of FAD mutant PS1 reduces the fast anterograde axonal transport of endogenous and transgenic APP.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataEnhancing Aβ accumulation per se does not lead to enhanced formation of axonal blockages, suggesting that the major route of generation of axonal phenotypes in APP transgenic mice is not a result of increasing levels of Aβ.
“Thus, enhancing Ab accumulation per se does not lead to enhanced formation of axonal blockages, suggesting that the major route of generation of axonal phenotypes in APP transgenic mice is not a result of increasing levels of Ab.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
Study design and conductnone givenMeasurements of varicosity diameters and lengths were made blind to the genotypes of the sections, with codes broken only after completion of data collection.
“These measurements were made 'blind' to the genotypes of the sections, which were coded.Codes were broken only after completion of the data collection.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). The quote only partly states this claim.
Study design and conductnone givenMice produced for behavioral analysis were coded for their genotypes at weaning, and codes were broken only upon completion of all tasks.
“WT, Tg-swAPP Prp , Tg-A246EPS1 Prp and Tg-swAPP Prp ; Tg-A246EPS1 Prp littermates produced for behavioral analysis were coded for their genotypes at weaning.”
Quote in the paperNot a substantial claimMay combine two claims.
Interpretationown dataAβ is sufficient, but not necessary, for the formation of neuritic defects.
“Thus, Ab is sufficient, but as we show here, and argue above, not necessary for the formation of neuritic defects.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [6] Meyer-Luehmann, 2008, Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer’s disease, Nature source
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductown dataCholinergic terminal data were collected blind by two independent observers and produced comparable final results.
“These data were also collected 'blind' to the genotypes of the sections by two independent observers (G.B.S. and E.M.R.) and produced comparable final results.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
Study design and conductnone givenAxonal pathology was scored blind to the genotypes by two independent observers.
“Axonal pathology was scored 'blind' to the genotypes by two independent observers (G.B.S. and E.M.R.).”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
PremisecitationLarge diameter axonal varicosities correspond to axonal swellings, a bona fide equivalent of axonal blockages at the light microscope level.
“Since previous work on cholinergic fibers in the BN found that large diameter axonal varicosities correspond to axonal swellings, a bona fide equivalent of axonal blockages at the light microscope level (7), we measured diameters and lengths of varicosities and inter-varicosity shafts”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [7] Stokin, 2005, Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease, Science source
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationOverexpression of mutant APP or mutant PS1, but not their combined overexpression, elevates cortical ChAT activity.
“For example, overexpression of mutant APP or mutant PS1, but not their combined overexpression, elevates cortical ChAT activity (62).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [62] Hernandez, 2001, Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes, Neuroreport source
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenExperimental samples with signal intensities within the linear range were quantified by two independent investigators, one blind to the genotypes.
“Experimental samples with signal intensities within the linear range were quantified by two independent investigators, one blind to the genotypes, using Image J (NIH) or Scion Image software (Scion Corporation).”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationFormation of these defects was enhanced by genetic reductions in kinesin-1 in Drosophila and in mice, where increased Aβ42/Aβ40 ratios and enhanced amyloid deposition were also observed.
“Formation of these defects was shown to be enhanced by genetic reductions in kinesin-1 in Drosophila (29,30) and in mice, where increased Ab42/Ab40 ratios and enhanced amyloid deposition were also observed (7,57).”
Quote in the paperNot a substantial claim0 of 2 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductnone givenWith rare exceptions, one mouse per genotype per trial was tested simultaneously and the position of each mouse changed between the trial days.
“With rare exceptions, we tested one mouse per genotype per trial simultaneously and the position of each mouse changed between the trial days.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductnone givenComparable areas of the BN were sampled with similar number of semithin and ultrathin sections from each mouse.
“Comparable areas of the BN were sampled with similar number of semithin and ultrathin sections from each mouse.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim. May combine two claims.
PremisecitationFusions of BRI-Aβ42 chimeras lead to synthesis and secretion of Aβ42 and amyloid deposition.
“Previous work revealed that fusions of BRI-Ab42 chimeras lead to synthesis and secretion of Ab42 and amyloid deposition (45).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [45] McGowan, 2005, Abeta42 is essential for parenchymal and vascular amyloid deposition in mice, Neuron source
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductcitationCharacterization of the Kif5B antibodies showed that these antibodies recognize primarily Kif5B (based on in vitro assays with Kif5A and Kif5C) and turned out to be exceptionally clean despite being crude sera.
“Characterization of the Kif5B antibodies showed that these antibodies recognize primarily Kif5B (based on the in vitro assays with Kif5A and Kif5C) and turned out to be exceptionally clean despite being crude sera (38,39).”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [38] Kamal, 2000, Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I, Neuron source
- cites [39] Kamal, 2001, Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP, Nature source
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductown dataThe two freezing response measurement methods are complimentary and results from both data sets were consistent with each other.
“These two freezing response measurement methods are complimentary and since results from both data sets were consistent with each other only data obtained by visual scoring are shown.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductnone givenAlmost all samples were examined on multiple gels and each gel on average by three to five different exposures.
“Almost all samples were examined on multiple gels and each gel on average by three to five different exposures.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationAxonal blockages in Drosophila and mice are thought to correspond to aberrant accumulations of proteins, vesicles and organelles within axons that block or otherwise inhibit normal axonal transport.
“Axonal blockages in Drosophila and mice are thought to correspond to aberrant accumulations of proteins, vesicles and organelles within axons that block or otherwise inhibit normal axonal transport (7,29,(48)(49)(50)(51).”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [7] Stokin, 2005, Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease, Science source
- cites [29] Gunawardena, 2001, Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila, Neuron source
- cites (48)(49)(50)(51)
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenQuantification of APP, Kif5B and SYD was normalized for a-tubulin and myelin basic protein.
“Quantification of APP, Kif5B and SYD was normalized for a-tubulin and myelin basic protein.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationTransgenic mice overexpressing APP which lack a caspase cleavage site in the C-terminal cytoplasmic region of APP generate large amounts of Ab peptides, but do not exhibit the significant cellular, synaptic and behavioral changes seen in matched transgenic mice producing comparable levels of Ab, but in which the caspase cleavage site is intact.
“These transgenic mice generate large amounts of Ab peptides, but they do not exhibit the significant cellular, synaptic and behavioral changes seen in matched transgenic mice producing comparable levels of Ab, but in which the caspase cleavage site is intact(63).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [63] Galvan, 2006, Reversal of Alzheimer’s-like pathology and behavior in human APP transgenic mice by mutation of Asp664, Proc. Natl Acad. Sci. USA source
May combine two claims. The quote only partly states this claim.
PremisecitationWhen Tg-BRI-Aβ42 Prp mice were crossed with Tg-swAPP Prp, the double transgenic mice had significantly increased RIPA-insoluble formic acid extracted Aβ40 and Aβ42 as well as enhanced amyloid deposition in several brain areas including BN compared with single transgenic Tg-swAPP Prp, Tg-BRI-Aβ40 Prp and BRI-Tg-Aβ42 Prp or Tg-swAPP Prp; Tg-BRI-Aβ40 Prp double transgenic littermates.
“In particular, when Tg-BRI-Ab42 Prp mice were crossed with Tg-swAPP Prp (53), the double transgenic Tg-swAPP Prp ; Tg-BRI-Ab42 Prp mice had significantly increased RIPA-insoluble formic acid extracted Ab40 and Ab42 as well as enhanced amyloid deposition in several brain areas including BN compared with single transgenic Tg-swAPP Prp”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [45] McGowan, 2005, Abeta42 is essential for parenchymal and vascular amyloid deposition in mice, Neuron source
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationAmyloid deposition occurs prior to neuritic defects.
“A recent in vivo dynamics study of cortical amyloid plaque formation found amyloid deposition prior to neuritic defects (6).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [6] Meyer-Luehmann, 2008, Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer’s disease, Nature source
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationGenetic reductions in kinesin-I also enhanced aberrant Aβ generation and amyloid deposition.
“These reductions also enhanced aberrant Ab generation and amyloid deposition (7).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [7] Stokin, 2005, Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease, Science source
The paper relies on this without support.
Directly varying APP levels alters APP domains in addition to Aβ.
“Because directly varying APP levels also alters APP domains in addition to Ab, we perturbed Ab generation selectively by combining APP transgenes in Drosophila and mice with presenilin-1 (PS1) transgenes harboring mutations that cause familial AD (FAD).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Mutant PS1 alone is said not to produce axonal pathology despite a reported increase in swellings
MinorThe discussion says transgenic FAD PS1 mutations cannot produce axonal pathology on their own, but the Figure 1 caption reports a significant increase in axonal swellings in mice expressing mutant PS1 alone.
“transgenic FAD PS1 mutations appear unable to produce axonal pathology as well as amyloid deposits on their own”
“between 2.7 and 3.6 mm (swellings) in Tg-A246EPS1 PrP (n ¼ 3, Ã means P 0.05)”
Cites
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · see citing works
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565 · see citing works
West, M. J., Slomianka, L., & Gundersen, H. J. G. (1991) · The Anatomical Record · doi:10.1002/ar.1092310411 · Cited by 2,994 · see citing works
Alzheimer's disease: cell-specific pathology isolates the hippocampal formation.
Hyman, B. T., Van Hoesen, G. W., Damasio, A. R., & Barnes, C. L. (1984) · Science · doi:10.1126/science.6474172 · Cited by 2,268 · cited 1× · see citing works
“in cognition( 2-4 ). These pathological changes produce impairments in several”
BackgroundA presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain
De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J., et al. (1999) · Nature · doi:10.1038/19083 · Cited by 2,100 · see citing works
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature · doi:10.1038/34910 · Cited by 1,818 · see citing works
Gundersen, H. J. G. (1986) · PubMed · Cited by 1,659 · see citing works
Borchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C.-M., Kim, G., Seekins, S., Yager, D., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80230-5 · Cited by 1,478 · see citing works
Stereology of arbitrary particles*
Gundersen, H. J. G. (1986) · Journal of Microscopy · doi:10.1111/j.1365-2818.1986.tb02764.x · Cited by 1,444 · see citing works
Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386 · see citing works
Self-citationRegulated Intramembrane Proteolysis
Brown, M. S., Ye, J., Rawson, R. B., & Goldstein, J. L. (2000) · Cell · doi:10.1016/s0092-8674(00)80675-3 · Cited by 1,329 · see citing works
Asher, R. (1961) · The Lancet · doi:10.1016/s0140-6736(61)91217-x · Cited by 1,293 · see citing works
Rovelet‐Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin‐Njock, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,249 · see citing works
Axonopathy and Transport Deficits Early in the Pathogenesis of Alzheimer’s Disease
Stokin, G. B., Lillo, C., Falzone, T. L., Brusch, R. G., Rockenstein, E., Mount, S. L., Raman, R., Davies, P., Masliah, E., Williams, D. S., et al. (2005) · Science · doi:10.1126/science.1105681 · Cited by 1,214 · see citing works
Self-citationNECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA
Perry, E., Perry, R., Blessed, G., & Tomlinson, B. E. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91780-9 · Cited by 1,070 · see citing works
Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053 · cited 1× · see citing works
“Ab levels were determined by endspecific sandwich-ELISA as previously described (45, 82 ).”
MethodBorchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S. (1997) · Neuron · doi:10.1016/s0896-6273(00)80974-5 · Cited by 1,023 · see citing works
Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease
Meyer-Luehmann, M., Spires-Jones, T. L., Prada, C., Garcia-Alloza, M., de Calignon, A., Rozkalne, A., Koenigsknecht-Talboo, J., Holtzman, D. M., Bacskai, B. J., & Hyman, B. T. (2008) · Nature · doi:10.1038/nature06616 · Cited by 987 · see citing works
Presenilin is required for activity and nuclear access of Notch in Drosophila
Struhl, G., & Greenwald, I. (1999) · Nature · doi:10.1038/19091 · Cited by 804 · see citing works
Katzman, R. (1986) · New England Journal of Medicine · doi:10.1056/nejm198604103141506 · Cited by 801 · see citing works
ULTRASTRUCTURAL STUDIES IN ALZHEIMER'S PRESENILE DEMENTIA.
Terry, R. D., Gonatas, N. K., & WEISS, M. (1964) · PubMed · Cited by 650 · see citing works
Gunawardena, S., Her, L.-S., Brusch, R. G., Laymon, R. A., Niesman, I. R., Gordesky-Gold, B., Sintasath, L., Bonini, N. M., & Goldstein, L. S. B. (2003) · Neuron · doi:10.1016/s0896-6273(03)00594-4 · Cited by 648 · see citing works
Self-citationKamal, A., Almenar-Queralt, A., LeBlanc, J. F., Roberts, E. A., & Goldstein, L. S. B. (2001) · Nature · doi:10.1038/414643a · Cited by 583 · see citing works
Self-citationAβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice
McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M. P., Beard, J., Das, P., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.030 · Cited by 565 · see citing works
Self-citationKamal, A., Stokin, G. B., Yang, Z., Xia, C.-H., & Goldstein, L. S. B. (2000) · Neuron · doi:10.1016/s0896-6273(00)00124-0 · Cited by 544 · see citing works
Self-citationSalehi, A., Delcroix, J.-D., Belichenko, P. V., Zhan, K., Wu, C., Valletta, J. S., Takimoto-Kimura, R., Kleschevnikov, A. M., Sambamurti, K., Chung, P. P., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.05.022 · Cited by 543 · see citing works
Self-citationHsiao, K., Borchelt, D., Olson, K., Johannsdottir, R., Kitt, C. A., Yunis, W. S., Xu, S., Eckman, C., Younkin, S. G., Price, D., et al. (1995) · Neuron · doi:10.1016/0896-6273(95)90107-8 · Cited by 519 · see citing works
Neurogenic phenotypes and altered Notch processing in Drosophila Presenilin mutants
Ye, Y., Lukinova, N. I., & Fortini, M. (1999) · Nature · doi:10.1038/19096 · Cited by 492 · see citing works
A stop-codon mutation in the BRI gene associated with familial British dementia
Vidal, R., Frangione, B., Rostagno, A., Mead, S., Révész, T., Plant, G., & Ghiso, J. (1999) · Nature · doi:10.1038/21637 · Cited by 466 · see citing works
Gunawardena, S., & Goldstein, L. S. B. (2001) · Neuron · doi:10.1016/s0896-6273(01)00496-2 · Cited by 428 · see citing works
Self-citationSleegers, K., Brouwers, N., Gijselinck, I., Theuns, J., Goossens, D., Wauters, J., Del‐Favero, J., Cruts, M., van Duijn, C. M., & Broeckhoven, C. V. (2006) · Brain · doi:10.1093/brain/awl203 · Cited by 406 · see citing works
THE FINE STRUCTURE OF NEUROFIBRILLARY TANGLES IN ALZHEIMERʼS DISEASE
Terry, R. D. (1963) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-196310000-00005 · Cited by 403 · see citing works
Lampert, P. W. (1967) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-196707000-00001 · Cited by 387 · see citing works
Alzheimer's disease. A double-labeling immunohistochemical study of senile plaques.
Dickson, D. W., Farlo, J., Davies, P., Crystal, H., Fuld, P. A., & Yen, S. H. (1988) · PubMed Central · Cited by 383 · see citing works
Hurd, D. D., & Saxton, W. M. (1996) · Genetics · doi:10.1093/genetics/144.3.1075 · Cited by 379 · see citing works
Aβ40 Inhibits Amyloid Deposition<i>In Vivo</i>
Kim, J., Onstead, L., Randle, S., Price, R., Smithson, L., Zwizinski, C., Dickson, D. W., Golde, T., & McGowan, E. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4849-06.2007 · Cited by 359 · see citing works
Self-citationEffects of PS1 Deficiency on Membrane Protein Trafficking in Neurons
Naruse, S., Thinakaran, G., Luo, J.-J., Kusiak, J. W., Tomita, T., Iwatsubo, T., Qian, X., Ginty, D. D., Price, D. L., Borchelt, D. R., et al. (1998) · Neuron · doi:10.1016/s0896-6273(00)80637-6 · Cited by 355 · see citing works
Holcomb, L. A., Gordon, M. N., Jantzen, P., Hsiao, K., Duff, K., & Morgan, D. (1999) · Behavior Genetics · doi:10.1023/a:1021691918517 · Cited by 353 · see citing works
Burger, P. C., & Vogel, F. S. (1973) · PubMed · Cited by 342 · see citing works
Phenotype associated with APP duplication in five families
Cabrejo, L., Guyant‐Maréchal, L., Laquerrière, A., Vercelletto, M., Fournière, F. D. L., Thomas-Antérion, C., Verny, C., Letournel, F., Pasquier, F., Vital, A., et al. (2006) · Brain · doi:10.1093/brain/awl237 · Cited by 342 · see citing works
Kinesin-Dependent Axonal Transport Is Mediated by the Sunday Driver (SYD) Protein
Bowman, A. B., Kamal, A., Ritchings, B. W., Philp, A. V., McGrail, M. A., Gindhart, J. G., & Goldstein, L. S. B. (2000) · Cell · doi:10.1016/s0092-8674(00)00162-8 · Cited by 331 · see citing works
Self-citationSunday Driver links axonal transport to damage signaling
Cavalli, V., Kujala, P., Klumperman, J., & Goldstein, L. S. B. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200410136 · Cited by 315 · see citing works
Self-citationMicrotubule Reduction in Alzheimer's Disease and Aging Is Independent of τ Filament Formation
Cash, A., Aliev, G. M., Siedlak, S. L., Nunomura, A., Fujioka, H., Zhu, X., Raina, A. K., Vinters, H. V., Tabaton, M., Johnson, T., et al. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64296-4 · Cited by 309 · see citing works
Alzheimer's Presenilin 1 Mutations Impair Kinesin-Based Axonal Transport
Pigino, G. F., Morfini, G. A., Pelsman, A., Mattson, M. P., Brady, S. T., & Busciglio, J. A. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-11-04499.2003 · Cited by 300 · see citing works
Vidal, R., Révész, T., Rostagno, A., Kim, E., Holton, J. L., Bek, T., Bojsen-Møller, M., Braendgaard, H., Plant, G., Ghiso, J., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.080076097 · Cited by 300 · see citing works
Axonal Transport and Alzheimer's Disease
Stokin, G. B., & Goldstein, L. S. B. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142637 · Cited by 292 · see citing works
Self-citationThe Pathogenesis of Alzheimer Disease: An Alternative to the Amyloid Hypothesis
Terry, R. D. (1996) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199655100-00001 · Cited by 291 · see citing works
Chen, X., Johnson, V. E., Uryu, K., Trojanowski, J. Q., & Smith, D. H. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00176.x · Cited by 267 · see citing works
APP Processing and Synaptic Plasticity in Presenilin-1 Conditional Knockout Mice
Yu, H., Saura, C. A., Choi, S., Sun, L. D., Yang, X., Handler, M., Kawarabayashi, T., Younkin, L. H., Fedeles, B. I., Wilson, M. A., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00417-2 · Cited by 255 · see citing works
Galvan, V., Gorostiza, O. F., Banwait, S., Ataie, M., Logvinova, A. V., Sitaraman, S., Carlson, E., Sagi, S. A., Chevallier, N., Jin, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509695103 · Cited by 239 · see citing works
Nishimura, M., Yu, G., Lévesque, G., Zhang, D. M., Ruel, L., Chen, F., Milman, P., Holmes, E., Liang, Y., Kawarai, T., et al. (1999) · Nature Medicine · doi:10.1038/5526 · Cited by 218 · see citing works
Dineley, K. T., Xia, X., Bui, D., Sweatt, J. D., & Zheng, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200164200 · Cited by 212 · see citing works
Torroja, L., Chu, H., Kotovsky, I., & White, K. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80215-2 · Cited by 203 · see citing works
Systematic Regional Variations in the Loss of Cortical Cholinergic Fibers in Alzheimer's Disease
Geula, C., & Mesulam, M.-M. (1996) · Cerebral Cortex · doi:10.1093/cercor/6.2.165 · Cited by 202 · cited 1× · see citing works
“Density of ChAT-IR fibers was approximated with a Weibel grid using an intersection approach ( 78 ,79).”
MethodCortical cholinergic fibers in aging and Alzheimer's disease: A morphometric study
Geula, C., & Mesulam, M. M. (1989) · Neuroscience · doi:10.1016/0306-4522(89)90399-0 · Cited by 202 · see citing works
Wong, T. P., Debeir, T., Duff, K., & Cuello, A. C. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02706.1999 · Cited by 196 · see citing works
Kaether, C., Lammich, S., Edbauer, D., Ertl, M., Rietdorf, J., Capell, A., Steiner, H., & Haass, C. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200201123 · Cited by 187 · see citing works
Galvan, V., Gorostiza, O. F., Banwait, S., Ataie, M., Logvinova, A., Sitaraman, S., Carlson, E., Sagi, S., Chevallier, N., Jin, K., et al. (2007) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0702342104 · Cited by 179
Jensen, E. B. V., & Gundersen, H. J. G. (1993) · Journal of Microscopy · doi:10.1111/j.1365-2818.1993.tb03321.x · Cited by 163 · see citing works
Fossgreen, A., Brückner, B., Czech, C., Masters, C. L., Beyreuther, K. T., & Paro, R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13703 · Cited by 156 · see citing works
In vivo axonal transport rates decrease in a mouse model of Alzheimer's disease
Smith, K. D. B., Kallhoff, V., Zheng, H., & Pautler, R. G. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.01.046 · Cited by 150 · see citing works
Neurochemical Diversity of Dystrophic Neurites in the Early and Late Stages of Alzheimer's Disease
Dickson, T. C., King, C., McCormack, G. H., & Vickers, J. C. (1999) · Experimental Neurology · doi:10.1006/exnr.1998.7010 · Cited by 144 · see citing works
Clinical Correlates of Cortical and Nucleus Basalis Pathology in Alzheimer Dementia
Samuel, W., Terry, R. D., DeTeresa, R. M., Butters, N., & Masliah, E. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540200048015 · Cited by 140 · see citing works
BACE overexpression alters the subcellular processing of APP and inhibits Aβ deposition in vivo
Lee, E. B., Zhang, B., Liu, K., Greenbaum, E. A., Doms, R. W., Trojanowski, J. Q., & Lee, V. M.-Y. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200407070 · Cited by 140 · see citing works
Lazarov, O., Morfini, G. A., Pigino, G. F., Gadadhar, A., Chen, X., Robinson, J., Ho, H., Brady, S. T., & Sisodia, S. S. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.4272-06.2007 · Cited by 135 · see citing works
Cai, D., Leem, J. Y., Greenfield, J. P., Wang, P., Kim, B. S., Wang, R., Radomski, K. L., Kim, S.-H., Zheng, H., Greengard, P., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209065200 · Cited by 132 · see citing works
Oyama, F., Cairns, N. J., Shimada, H., Oyama, R., Titani, K., & Ihara, Y. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62031062.x · Cited by 129 · see citing works
Nuclear Calcium/Calmodulin Regulates Memory Consolidation
Limbäck-Stokin, K., Korzus, E., Nagaoka-Yasuda, R., & Mayford, M. R. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.1022-04.2004 · Cited by 114 · see citing works
BRI2 (ITM2b) Inhibits A Deposition In Vivo
Kim, J., Miller, V. M., Levites, Y., West, K. J., Zwizinski, C. W., Moore, B. D., Troendle, F. J., Bann, M., Verbeeck, C., Price, R. W., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0891-08.2008 · Cited by 113 · see citing works
Self-citationDevelopment of senile plaques. Relationships of neuronal abnormalities and amyloid deposits.
Cork, L. C., Masters, C. L., Beyreuther, K. T., & Price, D. L. (1990) · Europe PMC (PubMed Central) · Cited by 112 · see citing works
Cai, D., Zhong, M., Wang, R., Netzer, W. J., Shields, D., Zheng, H., Sisodia, S. S., Foster, D. A., Gorelick, F. S., Xu, H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510710103 · Cited by 109 · see citing works
Masliah, E., Mallory, M. E., Hansen, L. A., Alford, M. F., DeTeresa, R. M., & Terry, R. D. (1993) · PubMed Central · Cited by 107 · see citing works
Ye, Y., & Fortini, M. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.6.1351 · Cited by 107 · see citing works
Re-Evaluation of the Structural Organization of Neuritic Plaques in Alzheimerʼs Disease
MASLIAH, E., MALLORY, M., DEERINCK, T., DETERESA, R., LAMONT, S., MILLER, A., TERRY, R. D., CARRAGHER, B., & ELLISMAN, M. (1993) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199311000-00009 · Cited by 105 · see citing works
Rasool, C. G., Svendsen, C. N., & Selkoe, D. J. (1986) · Annals of Neurology · doi:10.1002/ana.410200407 · Cited by 104 · see citing works
Kim, S., Leem, J. Y., Lah, J. J., Slunt, H. H., Levey, A. I., Thinakaran, G., & Sisodia, S. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108245200 · Cited by 102 · see citing works
Chromosomal Localization Reveals Three Kinesin Heavy Chain Genes in Mouse
Xia, C., Rahman, A., Yang, Z., & Goldstein, L. S. B. (1998) · Genomics · doi:10.1006/geno.1998.5427 · Cited by 76 · see citing works
Self-citationHernandez, D., Sugaya, K., Qu, T., McGowan, E., Duff, K., & McKinney, M. (2001) · Neuroreport · doi:10.1097/00001756-200105250-00018 · Cited by 73 · see citing works
Self-citationA Role for Presenilin 1 in Regulating the Delivery of Amyloid Precursor Protein to the Cell Surface
Leem, J. Y., Saura, C. A., Pietrzik, C. U., Christianson, J. C., Wanamaker, C., King, L. T., Veselits, M., Tomita, T., Gasparini, L., Iwatsubo, T., et al. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0546 · Cited by 72 · see citing works
Axonal atrophy: The retraction reaction
Bernstein, M. B., & Lichtman, J. W. (1999) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(99)80053-1 · Cited by 65 · see citing works
Sequestration of Tubulin in Neurons in Alzheimer's disease
Price, D. L., Altschuler, R. J., Struble, R. G., Casanova, M. F., Cork, L. C., & Murphy, D. B. (1986) · Brain Research · doi:10.1016/0006-8993(86)91077-2 · Cited by 55 · see citing works
Fossella, J., Samant, S. A., Silver, L. M., King, S. M., Vaughan, K. T., Olds‐Clarke, P., Johnson, K. A., Mikami, A., Vallee, R. B., & Pilder, S. H. (2000) · Mammalian Genome · doi:10.1007/s003350010003 · Cited by 53 · see citing works
In vivo imaging of axonal transport using MRI: aging and Alzheimer’s disease
Minoshima, S., & Cross, D. J. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0707-8 · Cited by 53 · see citing works
Rusu, P. M., Jansen, A., Soba, P., Kirsch, J., Loewer, A., Merdes, G., Kuan, Y., Jung, A. G., Beyreuther, K. T., Kjærulff, O., et al. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05341.x · Cited by 37 · see citing works
Linking molecular motors to Alzheimer’s disease
Stokin, G. B., & Goldstein, L. S. B. (2006) · Journal of Physiology-Paris · doi:10.1016/j.jphysparis.2005.12.085 · Cited by 32 · see citing works
Self-citationProteolysis and developmental signal transduction.
Ye, Y.-H., & Fortini, M. (2000) · Seminars in Cell and Developmental Biology · doi:10.1006/scdb.2000.0167 · Cited by 31 · see citing works
Fine Structural Changes of Neurites in Alzheimer’s Disease
Lampert, P. W. (1971) · Springer eBooks · doi:10.1007/978-3-642-47449-1_6 · Cited by 20 · see citing works
Microtubular interactions of presenilin direct kinesis of Aβ peptide and its precursors
Tezapsidis, N., MERZ, P. A., Merz, G., & Hong, H. (2003) · The FASEB Journal · doi:10.1096/fj.02-0980fje · Cited by 18 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Alzheimer's disease as homeostatic responses to age-related myelin breakdown
Bartzokis, G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.08.007 · Cited by 546 · see citing works
Lee, S., Satō, Y., & Nixon, R. A. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.6412-10.2011 · Cited by 471 · see citing works
“An excess of APP or specific APP metabolites may also alter vesicular transport (Stokin et al., 2008; Muresan et al., 2009).”
BackgroundDrosophila as an In Vivo Model for Human Neurodegenerative Disease
McGurk, L., Berson, A., & Bonini, N. M. (2015) · Genetics · doi:10.1534/genetics.115.179457 · Cited by 314 · see citing works
“This finding Alzheimer’s disease models APP Fossgreen et al. (1998); Greeve et al. (2004); Merdes et al. (2004); Muhammad et al. (2008); Stokin et al. (2008); Chakraborty et al. (2011); Mhatre et al. (2014) A-beta peptide Finelli et al. (2004); Iijima et al. (2004); Cao et al. (2008) PSEN 1 and 2…”
Drosophila melanogaster in the Study of Human Neurodegeneration
Hirth, F. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791556104 · Cited by 236 · see citing works
Gong, B., Radulovic, M., Figueiredo‐Pereira, M. E., & Cardozo, C. P. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00004 · Cited by 167 · see citing works
Chakraborty, R., Vepuri, V., Mhatre, S. D., Paddock, B. E., Miller, S., Michelson, S. J., Delvadia, R., Desai, A., Vinokur, M., Melicharek, D. J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020799 · Cited by 146 · see citing works
“transport defects [59].”
Self-citationLoss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease
Dawson, H. N., Cantillana, V., Jansen, M., Wang, H., Vitek, M. P., Wilcock, D. M., Lynch, J., & Laskowitz, D. T. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.04.037 · Cited by 137 · see citing works
Alzheimer's disease: insights from Drosophila melanogaster models
Moloney, A. M., Sattelle, D. B., Lomas, D. A., & Crowther, D. C. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.11.004 · Cited by 133 · see citing works
“This relatively complex model is ideal for the assessment of modulators of BACE1 or APP metabolism, but, in some respects, is more cumbersome than models in which the Aβ sequence is fused downstream of a secretion signal peptide [32,37–39].”
BackgroundThe contribution of glial cells to Huntington's disease pathogenesis
Wilton, D. K., & Stevens, B. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104963 · Cited by 112 · see citing works
“…cellular, morphological, physiological, and behavioral impairments observed in a variety of neurodegenerative diseases (Chakraborty et al., 2011; Elia et al., 1999; Greene et al., 2003; Mhatre et al., 2014; Nishimura et al., 2010; Stempfle et al., 2010; Stokin et al., 2008; Watson et al., 2008).”
BackgroundCytoplasmic dynein in neurodegeneration
Eschbach, J., & Dupuis, L. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.03.004 · Cited by 114 · see citing works
Woodruff, G., Reyna, S. M., Dunlap, M., van der Kant, R., Callender, J. A., Young, J. E., Roberts, E. A., & Goldstein, L. S. B. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.034 · Cited by 112 · see citing works
“These types of defects 770 Cell Reports 17, 759–773, October 11, 2016 could lead to previously reported axonal amyloid-dependent and -independent transport defects (Kim et al., 2015; Stokin et al., 2008; Vossel et al., 2015).”
Self-citationAxonal Stress Kinase Activation and Tau Misbehavior Induced by Kinesin-1 Transport Defects
Falzone, T. L., Stokin, G. B., Lillo, C., Rodrigues, E. M., Westerman, E. L., Williams, D. S., & Goldstein, L. S. B. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.0780-09.2009 · Cited by 102 · see citing works
“In fact, the realization that excess APP can poison the transport machinery through an A - independent mechanism (Gunawardena and Goldstein, 2001; Stokin et al., 2008) raises the possibility that NFT initiation could also be A -independent in some circumstances.”
BackgroundSelf-citationFolwell, J., Cowan, C. M., Ubhi, K. K., Shiabh, H., Newman, T. A., Shepherd, D., & Mudher, A. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.014 · Cited by 83 · see citing works
Modeling the complex pathology of Alzheimer's disease in Drosophila
Fernandez-Funez, P., de Mena, L., & Rincon-Limas, D. E. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.05.013 · Cited by 69 · see citing works
“Surprisingly, the combination of human APP and PS1 harboring familial AD mutations reduced the axonal blockade, indicating that full-length APP, not Aβ42, is responsible for these phenotypes (Stokin et al., 2008).”
BackgroundAxonal transport and neurodegenerative disease: Can we see the elephant?
Goldstein, L. S. B. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.03.006 · Cited by 67 · see citing works
Self-citationPresenilin controls kinesin-1 and dynein function during APP-vesicle transport in vivo
Gunawardena, S., Yang, G., & Goldstein, L. S. B. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt237 · Cited by 66 · see citing works
“Although early work suggested that PS1 can be transported bi-directionally in rat sciatic nerves (14,15), and from the entorhinal cortex to the hippocampus via axons of the perforant pathway (16), several recent observations support a direct role for PS in the modulation of axonal transport (17).”
BackgroundSelf-citationHahn, I., Voelzmann, A., Liew, Y.-T., Costa-Gomes, B., & Prokop, A. (2019) · Neural Development · doi:10.1186/s13064-019-0134-0 · Cited by 68 · see citing works
Falzone, T. L., Gunawardena, S., McCleary, D. F., Reis, G. F., & Goldstein, L. S. B. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq363 · Cited by 65 · see citing works
Self-citationRimal, S., Li, Y., Vartak, R. S., Geng, J., Tantray, I., Li, S., Huh, S., Vogel, H. S., Glabe, C. G., Grinberg, L. T., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01268-6 · Cited by 59 · see citing works
Modeling Alzheimer’s disease: from past to future
Saraceno, C., Musardo, S., Marcello, E. E., Pelucchi, S., & Luca, M. D. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00077 · Cited by 61 · see citing works
AD synapses contain abundant Aβ monomer and multiple soluble oligomers, including a 56-kDa assembly
Sokolow, S., Henkins, K. M., Bilousova, T. V., Miller, C. A., Vinters, H. V., Poon, W. W., Cole, G. M., & Gylys, K. H. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.011 · Cited by 57 · see citing works
Alzheimer's disease in a dish: promises and challenges of human stem cell models
Young, J. E., & Goldstein, L. S. B. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds319 · Cited by 56 · see citing works
Self-citationEnhanced -secretase processing alters APP axonal transport and leads to axonal defects
Rodrigues, E. M., Weissmiller, A. M., & Goldstein, L. S. B. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds297 · Cited by 55 · see citing works
Self-citationSivananthan, S., Lee, A. W., Goodyer, C. G., & LeBlanc, A. C. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.74 · Cited by 48 · see citing works
“These results confirmed Cell Death and Disease that the beading was dependent on Casp6 activity, but was independent of Ab.”
BackgroundInfluentialGenetic Dissection of Alzheimer’s Disease Using Drosophila Models
Jeon, Y., Lee, J., Choi, B., Won, S.-Y., & Cho, K. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030884 · Cited by 45 · see citing works
“However, it has been found that APP-induced axonal defects are not caused by Aβ [30], and that the APP intracellular domain is involved in various processes such as axonal transport and synaptic plasticity [31].”
BackgroundGan, K. J., & Silverman, M. A. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-12-1612 · Cited by 41 · see citing works
“Neurons cultured from AD mice expressing disease-associated mutations exhibit FAT defects (Pigino et al ., 2003; Lazarov et al ., 2007; Stokin et al ., 2008).”
Mureşan, V., & Muresan, Z. L. (2009) · Future Neurology · doi:10.2217/fnl.09.54 · Cited by 41 · see citing works
Hirota, Y., Sakakibara, Y., Ibaraki, K., Takei, K., Iijima, K., & Sekiya, M. (2022) · Brain Communications · doi:10.1093/braincomms/fcac286 · Cited by 39 · see citing works
Animal Models for Alzheimer’s Disease and Frontotemporal Dementia: A Perspective
Götz, J., & Götz, N. N. (2009) · ASN NEURO · doi:10.1042/an20090042 · Cited by 37 · see citing works
“However, by fusing the Ab domain with the BRI protein, it could be shown that the APP-induced axonal defects are not caused by Ab as one might have expected (Stokin et al., 2008).”
BackgroundYounan, N. D., Chen, K., Rose, R., Crowther, D. C., & Viles, J. H. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003319 · Cited by 38 · see citing works
Krstic, D., & Knuesel, I. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-62 · Cited by 36 · see citing works
“In addition, both a lack of APP [72] and an increase in proteolytic processing by γ-secretase [73] result in Aβ-independent [74] transport deficits.”
BackgroundDrosophila as a model to study age-related neurodegenerative disorders: Alzheimer's disease
Bonner, J. M., & Boulianne, G. L. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2010.08.004 · Cited by 31 · see citing works
Recent advances in using Drosophila to model neurodegenerative diseases
Lu, B. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0347-5 · Cited by 31 · see citing works
Grambaitė, R., Stenset, V. T. V., Reinvang, I., Walhovd, K. B., Fjell, A. M., & Fladby, T. (2009) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617709990932 · Cited by 30 · see citing works
Kang, M., Hansen, T. J., Mickiewicz, M., Kaczynski, T. J., Fye, S., & Gunawardena, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104617 · Cited by 29 · see citing works
Self-citationChristensen, D. Z., Hüttenrauch, M., Mitkovski, M., Pradier, L., & Wirths, O. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00139 · Cited by 27 · see citing works
“…in a variety of neurodegenerative diseases (Yagishita, 1978) and are suggested to strongly contribute to the pathological alterations underlying AD (Roy et al., 2005; Zhu et al., 2005; Stokin and Goldstein, 2006) and other diseases like e.g., lysosomal storage disorders (Ohara et al., 2004).”
BackgroundInfluentialLee, S., Bang, S. M., Hong, Y. K., Lee, J. H., Jeong, H., Park, S. H., Liu, Q. F., Lee, I., & Cho, K. S. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.018069 · Cited by 28 · see citing works
“Previous studies have shown that overexpression of APP induced axonal transport defects in both flies and mice, independently of Aβ peptides (Gunawardena and Goldstein, 2001; Stokin et al., 2008).”
Sakakibara, Y., Hirota, Y., Ibaraki, K., Takei, K., Chikamatsu, S., Tsubokawa, Y., Saito, T., Saido, T. C., Sekiya, M., & Iijima, K. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210385 · Cited by 26 · see citing works
“However, several studies have demonstrated that unphysiologically overexpressed A PP proteins impair axonal transport by interacting with kinesin [69] through c-Jun amino-terminal kinase interacting proteins [70] and cause axonopathy [69, 71, 72].”
BackgroundTrunova, S. A., & Giniger, E. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.008847 · Cited by 24 · see citing works
Gan, K. J., Akram, A., Blasius, T. L., Ramser, E. M., Budaitis, B. G., Gabrych, D. R., Verhey, K. J., & Silverman, M. A. (2020) · eNeuro · doi:10.1523/eneuro.0176-20.2020 · Cited by 16 · see citing works
“…can occur independent of tau and before overt morphologic decline and cell death, suggesting that early transport defects might play a causal role in AD pathogenesis (Pigino et al., 2003; Lazarov et al., 2007; Stokin et al., 2008; Goldstein, 2012; Rodrigues et al., 2012; Ramser et al., 2013).”
BackgroundLin, S., Leitao, A. D. G., Fang, S., Gu, Y., Barber, S., Gilliard-Telefoni, R., Castro, A., Sung, K., Shen, R., Florio, J. B., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106010 · Cited by 17 · see citing works
“Recent studies have demonstrated that disruption of axonal trafficking and processing of APP contribute to the early phase of AD pathogenesis (Brunholz et al., 2012; Rodrigues et al., 2012; Stokin et al., 2008; Stokin et al., 2005).”
BackgroundGan, K. J., Morihara, T., & Silverman, M. A. (2014) · BioEssays · doi:10.1002/bies.201400131 · Cited by 17 · see citing works
Banerjee, R., Rudloff, Z., Naylor, C., Yu, M. C., & Gunawardena, S. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy190 · Cited by 17 · see citing works
Self-citationMedina, C. S., Biris, O., Falzone, T. L., Zhang, X., Zimmerman, A. J., & Bearer, E. L. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.09.035 · Cited by 16 · see citing works
“In a background of Alzheimer’s models expressing mutant amyloid precursor protein (Stokin et al., 2008, 2005), or mutant tau protein (Falzone et al., 2010), KLC1 reduction enhances neuropathology with increased phospho-tau and amyloid, and varicosities in cholinergic axons (Falzone et al., 2010;…”
InfluentialSelf-citationImaging Amyloid Precursor Protein In Vivo: An Axonal Transport Assay
Falzone, T. L., & Stokin, G. B. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-536-7_25 · Cited by 16 · see citing works
Self-citationFiber Tracts Anomalies in APPxPS1 Transgenic Mice Modeling Alzheimer's Disease
Chen, H., Epelbaum, S., & Delatour, B. (2011) · Journal of Aging Research · doi:10.4061/2011/281274 · Cited by 15 · see citing works
Simple model systems: a challenge for Alzheimer's disease
Carlo, M. D. (2012) · Immunity & Ageing · doi:10.1186/1742-4933-9-3 · Cited by 15 · see citing works
“This Ab toxicity relatively complex model is ideal for the assessment of modulators of BACE1 or APP metabolism, but, in some aspects, is less easy to handle than the models in which the Ab sequence is fused downstream of a secretion signal peptide [41-43].”
BackgroundAlmenar-Queralt, A., Kim, S., Benner, C., Herrera, C., Kang, D. E., Garcia-Bassets, I., & Goldstein, L. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.513705 · Cited by 15 · see citing works
Self-citationAxonal transport and neurodegenerative disease: vesicle-motor complex formation and their regulation
Gunawardena, S., Anderson, E. N., & White, J. (2014) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s57502 · Cited by 15 · see citing works
Self-citationTackling neurodegenerative diseases: animal models of Alzheimer’s disease and Parkinson’s disease
Raslan, A., & Yun, K. (2013) · Genes & Genomics · doi:10.1007/s13258-013-0116-2 · Cited by 13 · see citing works
“Similarly, when human FAD APP is co-expressed with Drosophila FAD psn, flies display elevated levels of Ab42, enhanced amyloid deposition and neuronal apoptosis (Stokin et al. 2008).”
Wu, M., Li, Y., Miao, Y., Qiao, H., & Wang, Y. (2023) · Journal of drug targeting · doi:10.1080/1061186x.2023.2245582 · Cited by 9 · see citing works
Yoon, S. ‐., Choi, J. ‐., Cho, M., Yang, K., Ha, H., Chung, I. J., Cho, G. S., & Kim, D. H. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12032 · Cited by 9 · see citing works
Feole, M., Devoto, V. M. P., Dragišić, N., Arnaiz, C., Bianchelli, J., Texlova, K., Kovačovicova, K. L., Novotný, J., Havas, D., Falzone, T. L., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107137 · Cited by 8 · see citing works
“Early experiments showed that animal models carrying FAD pathogenic variants exhibit decreased APP levels at the proximal stump of ligated sciatic nerves and reduced Mn 2+ and NGF transport in the hippocamposeptal pathway (35, 36, 56, 57).”
BackgroundSelf-citationDifferential roles of Aβ processing in hypoxia-induced axonal damage
Christianson, M. G., & Lo, D. C. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.02.027 · Cited by 7 · see citing works
Banerjee, R., & Gunawardena, S. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1202307 · Cited by 7 · see citing works
“Interestingly, excess PS or excess PS loop rescued APP-induced axonal transport defects (Stokin et al., 2008).”
BackgroundSelf-citationBolshakova, O. I., Zhuk, A. A., Rodin, D., Kislik, G., & Sarantseva, S. V. (2014) · Russian Journal of Genetics Applied Research · doi:10.1134/s2079059714020026 · Cited by 6 · see citing works
“It has been also reported that besides the Aβ, the full length APP, as well as its other processing products, can contribute to neurodegener ation (Kim et al., 2003; Stokin et al., 2008; S omnicki and Les niak, 2008; Sarantseva et al., 2009).”
BackgroundSahara, N., & Lewis, J. M. (2010) · Future Neurology · doi:10.2217/fnl.10.10 · Cited by 5 · see citing works
sAPPα Inhibits Neurite Outgrowth in Primary Mouse Neurons via GABA B Receptor Subunit 1a
Barber, D., Salinas-Salinas, C., Houmam, S., Shukla, K., & Rice, H. C. (2026) · eNeuro · doi:10.1523/eneuro.0345-25.2026 · Cited by 4 · see citing works
A molecular dynamics study of the binary complexes of APP, JIP1, and the cargo binding domain of KLC
Taylor, C., Miller, B. R., Shah, S. S., & Parish, C. A. (2016) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25208 · Cited by 4 · see citing works
Neurodegenerative Diseases and Axonal Transport
Goldstein, L. S. B., & Das, U. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811304-2.00012-2 · Cited by 3 · see citing works
Self-citationHuman Diseases Associated with Notch Signalling: Lessons from Drosophila melanogaster
Megaly, M., Turgambayeva, A., Hallam, R. D., Foran, G., Megaly, M., & Necakov, A. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2906234 · Cited by 2 · see citing works
White Matter Changes: New Perspectives on Imaging, Clinical Aspects, and Intervention
Madureira, S., Verdelho, A., Pantoni, L., & Scheltens, P. (2011) · Journal of Aging Research · doi:10.4061/2011/841913 · Cited by 2 · see citing works
“cell proliferation, and promotion of angiogenesis [72, 73].”
BackgroundAPP Induces AICD ‐Mediated Autophagy‐Dependent Axon Degeneration
Luo, J., Qiu, Y., Pan, Y., Xu, R., Sun, Y. E., Sun, Y., Zhuang, L., Xue, E., Li, W., Zhou, Q., et al. (2025) · Aging Cell · doi:10.1111/acel.70301 · Cited by 1 · see citing works
“In line with this hypothesis, Stokin and co-workers have demonstrated that although the ratio of Aβ deposition remained unchanged, the level of axonal defects was suppressed when mutant PS1 was expressed in conjunction with APP (Stokin et al. 2008).”
Bolshakova, O. I., Zhuk, A. A., Rodin, D., Sarantseva, S. V., & Kislik, G. (2013) · Ecological genetics · doi:10.17816/ecogen11123-31 · Cited by 1 · see citing works
Reproductive and developmental toxicity models in relation to neurodegenerative diseases
Carlo, M. D. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-382032-7.10014-1 · Cited by 1 · see citing works
Notch Signaling: From Neurogenesis to Neurodegeneration
Sachan, N., Mutsuddi, M., & Mukherjee, A. (2019) · Springer eBooks · doi:10.1007/978-981-13-2218-1_7 · Cited by 1 · see citing works
Chen, M., Kretzschmar, D., Verdile, G., & Lardelli, M. T. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415894-8.00025-7 · Cited by 1 · see citing works
Cheng, G. W., Ma, I. W.-T., Huang, J., Yeung, S. H., Ho, P., Chen, Z., Mak, H. K., Herrup, K., Chan, K. W. Y., & Tse, K. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.24.547147 · Cited by 1 · see citing works
“To investigate if MTR findings above were the consequence of the intrinsic axonopathy reported 473 in similar APPSWE overexpression models (69-72), we applied DTI sequence to quantify the microstructural 474 integrity of the myelinated tracts, as exemplified by the slice at Bregma 0.”
InfluentialTRIAD (Transcriptional Repression‐Induced Atypical Death)
Tamura, T., & Okazawa, H. (2018) · doi:10.1002/9781119432463.ch20
Feole, M., & Stokin, G. B. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.17.516829
Self-citationRimal, S., Li, Y., Vartak, R. S., Geng, J., Tantray, I., Li, S., Huh, S., Vogel, H. S., Glabe, C., Grinberg, L. T., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16829900
Rôle des ADAM dans le processus physiopathologique de la maladie d'Alzheimer
Laumet, G. O. (2010) · theses.fr (ABES) · doi:10.70675/94126786zf990z488ezb471z5f1d5686766c
- Authors
- Stokin, G. B., Almenar-Queralt, A., Gunawardena, S., Rodrigues, E. M., Falzone, T., Kim, J., Lillo, C., Mount, S. L., Roberts, E. A., McGowan, E., Williams, D. S., & Goldstein, L. S. B.
- Affiliations
- Howard Hughes Medical Institute (US)
- Mayo Clinic (US)
- University of California San Diego (US)
- Corresponding author
- Goldstein, Lawrence S.B.
- ORCID
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-08-11
- Volume
- 17
- Issue
- 22
- Pages
- 3474-3486
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- PMC
- PMC2722897
- OpenAlex
- W2118694086
- Semantic Scholar
- 13d2199f0230c6ed399feb9764abbd4fb4a26413
- Cited by
- 72
- References
- 86
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 2 · 2018: 4 · 2016: 4 · 2015: 5 · 2014: 5 · 2013: 8 · 2012: 6
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Ellison Medical Foundation
- National Institutes of Health (5r01ey013408-11, EY13408)
- U.S. Public Health Service (AGO22595)
- National Institute on Aging
- National Eye Institute (R01 EY007042)
- National Institute of General Medical Sciences (GM 35252, R01GM035252)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid precursor protein, axonal transport, amyloid-beta, Alzheimer's disease, presenilin 1, familial Alzheimer's disease, APP overexpression, neuronal apoptosis, Aβ42/Aβ40 ratio, amyloid deposition, axonopathy
- MeSH terms
- Alzheimer Disease, Analysis of Variance, Animals, Axons, Axonal Transport, Behavior, Animal, Drosophila, Fear, Female, Humans, Immunohistochemistry, Male, Mice, Transgenic, Microscopy, Electron, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Transgenes, In Situ Nick-End Labeling, Mice, Presenilins, Cerebrum
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-17.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-17.
Cited sources are checked by gpt-6-sol.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review